Evidence map›Paper›PMID 40216786›Full record

ArticleScientific data2025

LUND-PROBE - LUND Prostate Radiotherapy Open Benchmarking and Evaluation dataset.

Viktor Rogowski, Lars E Olsson, Jonas Scherman, Emilia Persson, Mustafa Kadhim, Sacha Af Wetterstedt, Adalsteinn Gunnlaugsson, Martin P Nilsson, Nandor Vass, Mathieu Moreau and 5 more

Abstract readDataset
In one paragraph

Article in Scientific data, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Viktor RogowskiRadiation Physics, Department of Hematology, Oncology, and Radiation Physics, Skåne University Hospital, Lund, Sweden.
Lars E OlssonRadiation Physics, Department of Hematology, Oncology, and Radiation Physics, Skåne University Hospital, Lund, Sweden.
Jonas SchermanRadiation Physics, Department of Hematology, Oncology, and Radiation Physics, Skåne University Hospital, Lund, Sweden.
Emilia PerssonRadiation Physics, Department of Hematology, Oncology, and Radiation Physics, Skåne University Hospital, Lund, Sweden.
Mustafa KadhimRadiation Physics, Department of Hematology, Oncology, and Radiation Physics, Skåne University Hospital, Lund, Sweden.
Sacha Af WetterstedtRadiation Physics, Department of Hematology, Oncology, and Radiation Physics, Skåne University Hospital, Lund, Sweden.
Adalsteinn GunnlaugssonDepartment of Hematology, Oncology, and Radiation Physics, Skåne University Hospital, Lund, Sweden.
Martin P NilssonDepartment of Hematology, Oncology, and Radiation Physics, Skåne University Hospital, Lund, Sweden.
Nandor VassDepartment of Hematology, Oncology, and Radiation Physics, Skåne University Hospital, Lund, Sweden.
Mathieu MoreauDepartment of Hematology, Oncology, and Radiation Physics, Skåne University Hospital, Lund, Sweden.
Maria Gebre MedhinDepartment of Hematology, Oncology, and Radiation Physics, Skåne University Hospital, Lund, Sweden.
Sven BäckRadiation Physics, Department of Hematology, Oncology, and Radiation Physics, Skåne University Hospital, Lund, Sweden.
Per Munck Af RosenschöldRadiation Physics, Department of Hematology, Oncology, and Radiation Physics, Skåne University Hospital, Lund, Sweden.
Silke EngelholmDepartment of Hematology, Oncology, and Radiation Physics, Skåne University Hospital, Lund, Sweden.
Christian Jamtheim GustafssonRadiation Physics, Department of Hematology, Oncology, and Radiation Physics, Skåne University Hospital, Lund, Sweden. Christian.JamtheimGustafsson@skane.se.ORCID http://orcid.org/0000-0003-2931-5615

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Radiotherapy treatment for prostate cancer relies on computed tomography (CT) and/or magnetic resonance imaging (MRI) for segmentation of target volumes and organs at risk (OARs). Manual segmentation of these volumes is regarded as the gold standard for ground truth in machine learning applications, but to acquire such data is tedious and time-consuming. A publicly available clinical dataset is presented, comprising MRI- and synthetic CT (sCT) images, target and OARs segmentations, and radiotherapy dose distributions for 432 prostate cancer patients treated with MRI-guided radiotherapy. An extended dataset with 35 patients is also included, with the addition of deep learning (DL)-generated segmentations, DL segmentation uncertainty maps, and DL segmentations manually adjusted by four radiation oncologists. The publication of these resources aims to aid research in automated radiotherapy treatment planning, segmentation, inter-observer analyses, and DL model uncertainty investigation. The dataset is hosted on the AIDA Data Hub and offers a free-to-use resource for the scientific community, valuable for the advancement of medical imaging and prostate cancer radiotherapy research.

Indexed as

Prostatic NeoplasmsBenchmarkingDeep LearningHumansMagnetic Resonance ImagingMaleRadiotherapy, Image-GuidedRadiotherapy Planning, Computer-AssistedTomography, X-Ray Computed

Identifiers

PMID40216786
PMCPMC11992069

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.